dehydroepiandrosterone has been researched along with Dyskinesia, Drug-Induced in 4 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to investigate for the first time efficacy of DHEA augmentation with standardized antipsychotic medication (olanzapine) and to explore effects of DHEA augmentation on side-effect profiles including weight gain, glucose tolerance, aggression, quality of life and neurocognitive function." | 9.12 | Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. ( Eisner, D; Gal, G; Katz, E; Maayan, R; Strous, RD; Stryjer, R; Viglin, D; Weizman, A, 2007) |
| " The aim of this study was to investigate for the first time efficacy of DHEA augmentation with standardized antipsychotic medication (olanzapine) and to explore effects of DHEA augmentation on side-effect profiles including weight gain, glucose tolerance, aggression, quality of life and neurocognitive function." | 5.12 | Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. ( Eisner, D; Gal, G; Katz, E; Maayan, R; Strous, RD; Stryjer, R; Viglin, D; Weizman, A, 2007) |
| "The goals of this study were to determine whether alterations in serum dehydroepiandrosterone (DHEA), its sulfated conjugate (DHEAS), androstenedione, testosterone, and progesterone concentrations occur in schizophrenia patients compared with healthy controls over two months, and their associations with psychopathology, emotional distress, and antipsychotic treatment." | 3.73 | Alterations in DHEA metabolism in schizophrenia: two-month case-control study. ( Gibel, A; Maayan, R; Ram, E; Ritsner, M; Weizman, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ritsner, MS | 1 |
| Gibel, A | 2 |
| Shleifer, T | 1 |
| Boguslavsky, I | 1 |
| Zayed, A | 1 |
| Maayan, R | 3 |
| Weizman, A | 3 |
| Lerner, V | 1 |
| Ritsner, M | 1 |
| Ram, E | 1 |
| Bélanger, N | 1 |
| Grégoire, L | 1 |
| Bédard, PJ | 1 |
| Di Paolo, T | 1 |
| Strous, RD | 1 |
| Stryjer, R | 1 |
| Gal, G | 1 |
| Viglin, D | 1 |
| Katz, E | 1 |
| Eisner, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Addition of Both Pregnenolone and L-theanine to Ongoing Antipsychotic Treatment for Schizophrenia and Schizoaffective Disorders: an 8-week, Randomized, Double-blind, Placebo-controlled Multicenter Study[NCT01831986] | 60 participants (Anticipated) | Interventional | 2011-01-31 | Enrolling by invitation | |||
| Efficacy and Safety of Pregnenolone Augmentation in the Management of Schizophrenia Patients: a Randomised Double-Blind Placebo-Controlled Trial[NCT00174889] | Phase 1 | 60 participants | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for dehydroepiandrosterone and Dyskinesia, Drug-Induced
2 other studies available for dehydroepiandrosterone and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Alterations in DHEA metabolism in schizophrenia: two-month case-control study.
Topics: Adult; Aging; Androstenedione; Antipsychotic Agents; Anxiety; Case-Control Studies; Dehydroepiandros | 2006 |
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dehydroepiandrosterone; | 2006 |